📊 KZR Key Takeaways
Is Kezar Life Sciences, Inc. (KZR) a Good Investment?
Kezar Life Sciences presents a paradoxical fundamental profile: exceptional financial health with $71.9M cash, zero debt, and improving operational losses, yet faces acute execution risk as a pre-revenue pharmaceutical company with ~16 months of runway at current burn rates. The solid balance sheet provides strategic flexibility, but the outcome depends entirely on clinical trial success and FDA approvals rather than operational fundamentals.
Kezar is a pre-revenue biotech with sustained operating losses and negative free cash flow, offset by a sizable cash balance and no debt. At the current burn (~$52M OCF) versus ~$72M cash, liquidity covers roughly 12–18 months before likely external financing is needed. Despite YoY loss improvement, fundamentals show no near-term path to profitability or revenue.
Why Buy Kezar Life Sciences, Inc. Stock? KZR Key Strengths
- Exceptional liquidity with $71.9M cash reserve against only $6.6M liabilities, providing substantial operational flexibility
- Zero debt and minimal capital requirements reduce refinancing risk and preserve strategic options
- Operating losses improving 33.1% year-over-year, suggesting operational discipline or progress toward clinical milestones
- Strong stockholders equity of $70.1M relative to asset base indicates clean balance sheet
- Strong liquidity with 11.5x current ratio and ~$72M cash
- Debt-free balance sheet; minimal fixed obligations
- YoY improvement in net loss and negligible capex
KZR Stock Risks: Kezar Life Sciences, Inc. Investment Risks
- Pre-revenue status with zero commercial traction creates binary outcome dependency on unproven pipeline
- Annual cash burn of $51.8M against reserves yields only ~16 months runway, requiring near-term capital raise
- Existential clinical and regulatory risk - all enterprise value depends on FDA approvals for experimental drugs
- Shareholder dilution likely from future equity financing rounds needed before profitability
- No disclosed insider buying activity in 90 days, suggesting limited management conviction at current burn trajectory
- No revenue and persistent large operating losses
- Cash runway likely under two years, implying financing/dilution risk
- Negative ROE/ROA and interest coverage reflect weak profitability trajectory
Key Metrics to Watch
- Quarterly cash burn trend and updated runway - early indicator of financing urgency
- Clinical trial enrollment, efficacy data releases, and FDA milestone announcements for pipeline programs
- Partnership announcements or licensing deals indicating external validation of asset value
- Operating cash flow (burn rate)
- Cash & equivalents (runway)
Kezar Life Sciences, Inc. (KZR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 11.52x current ratio provides a solid financial cushion.
KZR Profit Margin, ROE & Profitability Analysis
KZR vs Healthcare Sector: How Kezar Life Sciences, Inc. Compares
How Kezar Life Sciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Kezar Life Sciences, Inc. Stock Overvalued? KZR Valuation Analysis 2026
Based on fundamental analysis, Kezar Life Sciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Kezar Life Sciences, Inc. Balance Sheet: KZR Debt, Cash & Liquidity
KZR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Kezar Life Sciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-14.04 indicates the company is currently unprofitable.
KZR Revenue Growth, EPS Growth & YoY Performance
KZR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$20.3M | $-2.78 |
| Q3 2023 | N/A | -$16.0M | $-0.25 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Kezar Life Sciences, Inc. Dividends, Buybacks & Capital Allocation
KZR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Kezar Life Sciences, Inc. (CIK: 0001645666)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KZR
What is the AI rating for KZR?
Kezar Life Sciences, Inc. (KZR) has a Combined AI Rating of SELL from Claude (HOLD) and ChatGPT (SELL) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KZR's key strengths?
Claude: Exceptional liquidity with $71.9M cash reserve against only $6.6M liabilities, providing substantial operational flexibility. Zero debt and minimal capital requirements reduce refinancing risk and preserve strategic options. ChatGPT: Strong liquidity with 11.5x current ratio and ~$72M cash. Debt-free balance sheet; minimal fixed obligations.
What are the risks of investing in KZR?
Claude: Pre-revenue status with zero commercial traction creates binary outcome dependency on unproven pipeline. Annual cash burn of $51.8M against reserves yields only ~16 months runway, requiring near-term capital raise. ChatGPT: No revenue and persistent large operating losses. Cash runway likely under two years, implying financing/dilution risk.
What is KZR's revenue and growth?
Kezar Life Sciences, Inc. reported revenue of $0.0.
Does KZR pay dividends?
Kezar Life Sciences, Inc. does not currently pay dividends.
Where can I find KZR SEC filings?
Official SEC filings for Kezar Life Sciences, Inc. (CIK: 0001645666) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KZR's EPS?
Kezar Life Sciences, Inc. has a diluted EPS of $-7.66.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KZR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Kezar Life Sciences, Inc. has a SELL rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KZR stock overvalued or undervalued?
Valuation metrics for KZR: ROE of -80.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KZR stock in 2026?
Our dual AI analysis gives Kezar Life Sciences, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KZR's free cash flow?
Kezar Life Sciences, Inc.'s operating cash flow is $-51.8M, with capital expenditures of $8.0K.
How does KZR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -80.0% (avg: 15%), current ratio 11.52 (avg: 2).